Saturday 17 October 2026
Export ATEC’s income statement to Excel — free account
Alphatec Holdings, Inc.
ATEC Healthcare Medical Devices
Alphatec Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $764.2 million, up 25.0% from fiscal 2024. In the quarter to June 2026, revenue grew 15.1%, EPS grew 40.7%, free cash flow fell 146.9% and total debt fell 7.79%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
10.45
0.48
−4.39%
Follow ATEC
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
1.66 | 2.13 | 4.13 | 3.02 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
66.03 | 1,298.28 | 152.66 | 156.79 | |
P/B ratio |
0.00 | 0.00 | 254.09 | 191.32 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
2.22 | 2.68 | 4.66 | 3.58 | |
EV/EBITDA |
29.31 | 43.67 | 155.25 | 821.61 | |
EV/Operating CF |
32.04 | 40.90 | 78.76 | 74.28 | |
EV/FCF |
(315.58) | (2,696.57) | (807.85) | (777.70) | |
Quick Ratio |
0.96 | 1.03 | 1.18 | 1.14 | |
Current Ratio |
1.89 | 1.90 | 2.06 | 1.99 | |
Net Debt/EBITDA |
14.28 | 79.25 | 18.36 | 36.23 | |
Debt/Assets |
64.57% | 63.53% | 63.37% | 71.09% | |
Debt/Equity |
(42.32) | (94.99) | 40.35 | 48.64 | |
Asset Turnover |
1.03 | 0.99 | 0.98 | 0.95 | |
Operating CF/Net income |
(0.80) | (0.04) | (0.95) | (0.49) | |
Capex/Depreciation |
(0.75) | (0.53) | (0.55) | (0.40) | |
Interest Coverage |
(0.17) | (1.93) | (0.68) | (1.24) | |
Research and Development Expense of Revenue |
8.51% | 9.14% | 10.68% | 9.51% | |
Selling, General and Administrative Expense of Revenue |
62.76% | 71.34% | 60.44% | 63.26% | |
Intangible Assets out of Total Assets |
0.21 | 0.21 | 0.21 | 0.22 | |
Share Based Compensation of Revenue |
8.50% | 12.32% | 9.11% | 8.34% | |
Graham Net Nets |
(0.26) | (0.21) | (0.10) | (0.15) | |
Graham Number |
1.11 | 0.80 | 0.00 | 0.00 | |
Earnings Yield |
(8.21%) | (7.54%) | (4.52%) | (7.15%) | |
Free Cash Flow Yield |
(0.42%) | (0.05%) | (0.14%) | (0.15%) | |
Revenue per Share |
1.36 | 1.25 | 1.42 | 1.30 | |
Operating CF per Share |
0.13 | 0.01 | 0.14 | 0.09 | |
Capex per Share |
(0.14) | (0.09) | (0.10) | (0.07) | |
Free Cash Flow per Share |
(0.01) | (0.08) | 0.04 | 0.02 | |
Cash per Share |
0.76 | 0.91 | 1.07 | 1.03 | |
Shareholders Equity per Share |
(0.08) | (0.03) | 0.08 | 0.08 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.08) | (0.03) | 0.08 | 0.08 | |
Free Cash Flow |
(1.58) | (13.02) | 5.72 | 3.15 | |
Working Capital |
211.05 | 215.92 | 231.70 | 218.95 | |
Capital Expenditures |
(22.09) | (14.31) | (14.96) | (10.89) | |
Net Current Asset Value |
(354.08) | (348.66) | (327.91) | (335.96) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.10 | 0.07 | 0.07 | 0.06 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
103.02 | 97.93 | 90.15 | 87.65 | |
Average Payables |
54.67 | 42.40 | 46.94 | 48.23 | |
Average Inventory |
182.32 | 178.45 | 172.35 | 175.00 | |
Average Assets |
790.66 | 792.48 | 783.46 | 766.57 | |
Average Common Equity |
5.85 | (45.64) | (0.87) | 5.07 |
Columns are period end dates